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A B S T R A C T
While studies have demonstrated that the main psychoactive component of cannabis, Δ9-tetrahydrocannabinol
(Δ9-THC) alone induces placental insufficiency and fetal growth restriction, the underlying mechanisms remain
elusive. Given that both (i) endoplasmic reticulum (ER) stress in pregnancy and (ii) gestational exposure to
Δ9-THC leads to placental deficiency, we hypothesized that Δ9-THC may directly induce placental ER stress,
influencing trophoblast gene expression and mitochondrial function. BeWo human trophoblast cells treated with
Δ9-THC (3–30 μM) led to a dose-dependent increase in all ER stress markers and CHOP; these effects could
be blocked with CB1R/CB2R antagonists. Moreover, expression of ER stress-sensitive genes ERRγ, VEGFA, and
FLT-1 were increased by Δ9-THC, and abrogated with the ER stress inhibitor TUDCA. Δ9-THC also diminished
mitochondrial respiration and ATP-coupling due to decreased abundance of mitochondrial chain complex pro-
teins. Collectively, these findings indicate that Δ9-THC can directly augment ER stress resulting in aberrant pla-
cental gene expression and impaired mitochondrial function.
1. Introduction
Cannabis is the most frequently used illicit drug in the world hav-
ing an estimated 140 million consumers; with the impending shift
towards legalizing recreational cannabis use this number of users is
only expected to rise [1]. Among pregnant women in North Amer-
ica, recent studies indicate nearly 1 in 5 women (18–24 years) were
using cannabis during pregnancy [2]. Moreover, while the rates of
smoking cannabis in pregnancy have steadily increased from 2002 to
2014, it has also been reported that more women would use cannabis
in pregnancy if it were legalized [3]. Women who continue to use
cannabis while pregnant may do so to mitigate nausea, anxiety, and
lack of appetite [4]. For example, a survey of women in Vancouver,
Canada found that 77% of cannabis use during pregnancy was related
to the common conception that it will reduce nausea symptoms [4].
While systematic reviews and meta-analyses demonstrate that mater-
nal cannabis use results in low birth weight outcomes, these studies
are confounded by sociodemographic influences and the fact that many
cannabis users also use other drugs (e.g. tobacco) [5–9]. The major psy-
choactive cannabinoid in cannabis, Δ9-tetrahydrocannabinol (Δ9-THC)
can cross the placenta and animal studies indicate that 10% of maternal
concentrations can be found in fetal plasma, with 2–5 times higher con-
centration in fetal tissues [10–12]. This is of great concern considering
that due to selective growing methods, the concentration of Δ9-THC in
cannabis has increased from 3% to 12% over the last decade [13]. In an-
imal models, fetal exposure to Δ9-THC alone during gestation leads to
placental insufficiency and fetal growth restriction, but the underlying
mechanisms remain incompletely understood [14,15].
The molecular targets of action for Δ9-THC in the placenta are the
two G-coupled cannabinoid receptors CB1R and CB2R, part of the en-
docannabinoid system [16,17]. CB1R and CB2R are found in heart,
embryo, uterus, placenta, peripheral blood lymphocytes while CB1R
is found predominantly in central nervous system [17]. The endo-
cannabinoid system has a role in reproduction from the early stages of
fertilization, embryo implantation, and placentation [18]. In the pla
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centa, cannabinoid receptors have been detected in early first and third
trimester placental tissues [18]. Interestingly, the levels of endogenous
cannabinoid anandamide decrease gradually during pregnancy as high
systemic levels of endogenous cannabinoids impede normal pregnancy
progression [18,19]. Δ9-THC in cannabis is able to bind to these same
cannabinoid receptors and activate them in a similar manner as endoge-
nous cannabinoids.
The majority of knowledge evaluating the effects of Δ9-THC alone
on the placenta and fetal development arises from animal studies. In
rodents, exposure of pregnant dams to Δ9-THC during gestation led to
placental insufficiency and low birth weight offspring [14,15]. In hu-
man BeWo placental trophoblasts, Δ9-THC impairs proliferation, inva-
sion and migration [14,20]. However, the mechanism of action linking
Δ9-THC exposure and fetal growth restriction mediated via placental in-
sufficiency remain incompletely understood.
Recent studies have suggested that endoplasmic reticulum (ER)
stress plays a role in etiology of intrauterine growth restriction. The ER
is responsible for many functions within the cell, one of which being
protein synthesis [21]. ER stress is induced from an accumulation of
misfolded and unfolded proteins in the ER lumen [21]. To restore ER
homeostasis, the uncoupled protein response (UPR) is activated through
three signaling pathways: ATF6, IRE1α, and PERK [22]. The first path-
way involves increases in chaperone proteins such as glucose regulated
protein 78 (GRP78) which are responsible for enhancing and assisting
with protein folding [22]. The second pathway, IRE1 is involved in fur-
ther upregulation of chaperone proteins and protein degradation, in part
due to increases in the expression of the transcription factor, spliced
XBP-1 [21]. Finally, the PERK pathway (i.e. increases in ATF4) is in-
volved in the attenuation of protein translation via phosphorylation of
eukaryotic initiation factor (P-eIF2α) in order to reduce the amount of
new proteins entering the ER lumen [22]. However, if UPR fails to al-
leviate ER stress, downstream apoptotic pathways are activated, medi-
ated through C/EBP-homologous protein/Gadd153 (CHOP), which has
been associated with compromised placental development and func-
tion (i.e. IUGR, gestational diabetes, and preeclampsia) in vivo and in
vitro [23–28]. Moreover, during mouse pregnancy, when pregnant dams
were administered a single dose of tunicamycin (which inhibits N-linked
glycosylation) to pharmacologically induce ER stress, this led to lower
placental and fetal weight outcomes due in part to placental abnormal-
ities in nutrient transport and in the aberrant expression of genes in-
volved in angiogenesis [29]. Together, this research suggests that induc-
tion of ER stress is one driver of placental insufficiency and fetal growth
restriction [29].
Given that (i) treatment with Δ9-THC during pregnancy in vivo leads
to placental deficiency and fetal growth restriction [14,15,30]; and that
(ii) ER stress is associated with both placental dysfunction and impeded
fetal growth [29], we hypothesized that administration of Δ9-THC to
placental cells will induce ER stress leading to aberrant trophoblast gene
expression. The aim of this study was to further understand the cellu-
lar mechanism of previously reported Δ9-THC-induced placental insuf-
ficiency by directly investigating the relationship between Δ9-THC ex-
posure and placental ER stress in human BeWo trophoblast cells. BeWo
cells are a choriocarcinoma cell line derived from first trimester villous
trophoblasts which have been widely used as an in vitro model to ex-
amine the effects of drugs (i.e. Δ9-THC, ethanol, nicotine) on placental
function [14,20,31,32]. Given the integration of the ER and mitochon-
dria in the placenta [33], we also sought to examine if Δ9-THC induced
ER stress was also associated with placental mitochondrial dysfunction.
2. Materials and methods
2.1. Cell culture
BeWo human trophoblast cell line was used as a model of the hu-
man placenta in vitro. The BeWo cell line derives from a human ges-
tational choriocarcinoma, and is a known cellular model of the human
trophoblast, having been widely used as an in vitro model for drug (i.e.
Δ9-THC) studies [14,20,31]. Cells were maintained (passages 8–18) at
37 °C and 5% CO⁠2/95% atmospheric air in cell culture incubator. Cells
were cultured in 75-cm⁠2 flasks in F-12 K Nutrient medium (Gibco) with
10% fetal bovine serum (Gibco) and 1% P/S.
2.2. Δ9-THC treatments
To test the effect of Δ9-THC on ER stress in BeWo cells, the cells
were plated on a 12-well plate with 2 × 10⁠5 cells per well 1 mL of
F-12 K Nutrient medium and were seeded for 24 h prior treatment. The
medium was changed to one that contained increasing concentrations
(e.g. 3–30 μM) of Δ9-THC (dissolved in final concentration of 0.1%(v/v)
ethanol, Cayman Chemicals, Ann Arbor, MI) for 24 h. The vehicle con-
sisted of culture medium containing 0.1%(v/v) ethanol. The doses of
Δ9-THC were chosen based on previous pharmacokinetic studies which
determined equivalent doses to those found in the serum of cannabis
users [20,34]. The 24-hour time-point allowed for detection of changes
in the mRNA and protein involved in the UPR which indicated activa-
tion of placental ER stress, as we have demonstrated previously with
nicotine, a known trigger of ER stress [35].
2.3. CB1R and CB2R antagonist treatments
To block the effects of Δ9-THC on the cannabinoid receptors, cells
were treated with CB1R and CB2R antagonists SR141716 and SR144528
respectively. BeWo cells were plated onto 12-well plate and were
pre-treated with 1 μM SR141716, 0.1 μM SR144528, or both for 1 h and
then treated with 15 μM Δ9-THC solution for 24 h. We chose 15 µM
as a mid-range dose and that did not affect cellular viability in BeWo
cells [14,20]. These concentrations of the SR141716 and SR144528
have been previously demonstrated to ameliorate the detrimental ef-
fects of Δ9-THC on migration in both BeWo and human umbilical vein
endothelial cells (HUVEC) cells but alone had no significant effect on
BeWo cell migration [14,36].
2.4. Amelioration of ER stress - TUDCA treatments
To prevent Δ9-THC-induced ER stress, we used tauroursodeoxy-
cholic acid (TUDCA); TUDCA has been shown to relieve ER stress in
several cell and tissue types, including the placenta [35,37]. After seed-
ing cells in 12-well plate, cells were pretreated for 1 h with 100 μM of
TUDCA (Sigma-Aldrich), and then treated with 15 μM Δ9-THC for 24 h.
This dose of TUDCA has been effective to ameliorate nicotine-induced
ER stress and UPR activation in rat Rcho-1 trophoblast giants cells af-
ter 24 h[35]. Additionally, BeWo cells were also treated with 15 μM
11−COOH-THC (Sigma-Aldrich), the inactive THC metabolic, to assess
its potential effects on ER stress.
2.5. RNA extraction and real time-polymerase chain reaction
Total RNA was extracted from cells using TRIzol reagent (Invit-
rogen). Chloroform (Sigma-Aldrich) was added to the solution, and
then centrifuged at 12,500 rpm. Supernatant was transferred to a fresh
tube with an equal volume of isopropanol (Sigma-Aldrich) and cen-
trifuged again at 12,500 rpm. Total RNA was then collected from the
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pellet and dissolved in DEPC-treated water. Deoxyribonuclease I, Am-
plification Grade (Invitrogen) was added to the RNA to digest contami-
nating single- and double-stranded DNA. Four micrograms of RNA were
reverse-transcribed to cDNA using random hexamers and Superscript
II Reverse Transcriptase (Invitrogen). Primer sets directed against gene
targets of interest were designed through National Center for Biotech-
nology Information’s primer designing tool and generated via Invitrogen
Custom DNA Oligos (Table 1). Quantitative analysis of mRNA expres-
sion was performed via RT-PCR using fluorescent nucleic acid dye Sso-
Fast EvaGreen supermix (BioRad) and BioRad CFX384 Real Time Sys-
tem. The cycling conditions were 95 °C for 10 min, followed by 43 cycles
of 95 °C for 15 s and 60 °C for 30 s and 72 °C for 30 s. The cycle thresh-
old was set so that exponential increases in amplification were approxi-
mately level between all samples. Relative fold changes were calculated
using the comparative cycle times (Ct) method, normalizing all val-
ues to the geometric mean of the housekeeping gene, GAPDH. GAPDH
was determined as a suitable housekeeping gene using algorithms from
GeNorm, Normfinder, BestKeeper, and the comparative ΔCt method to
place it as the most stable housekeeping gene from those tested (e.g.
β-actin, 18S ribosomal RNA) [38–41]. Given all primer sets had equal
priming efficiency, the ΔCt values for each primer set were calibrated
to the average of all control Ct values, and the relative abundance of
each primer set compared with calibrator was determined by the for-
mula 2⁠ΔΔCt, in which ΔΔCt was the normalized value.
2.6. Protein extraction and Western blot
BeWo cells were homogenized in RIPA buffer (50 mM Tris−HCL, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.25% C⁠24H⁠39NaO⁠4,
supplemented with phosphatase inhibitors (20 mM NaF, 40 mM Na-py-
rophosphate, 40 mM Na⁠3VO⁠4, 200 mM β-glycerophosphate disodium
salt hydrate), and a protease inhibitor cocktail (Roche)). The solution
was sonicated at 30% amplitude for 5 s total, 1 s per pulse. It was then
mixed in a rotator for 10 min at 4 °C and centrifuged at 16,000 g for
20 min at 4 °C. The resulting supernatant was collected as the total
cellular protein extract and quantified by colorimetric DC protein as-
say (BioRad). Loading samples were prepared with fresh total pro-
tein extract (avoiding repeated freeze-thaw cycles), NuPAGE LDS Sam-
ple Buffer (4X) (Invitrogen), NuPAGE Reducing Agent (10X) (Invitro-
gen), and deionized water, and heated at 70 °C for 10 min to denature
the proteins. Proteins (20 μg/well) were separated by size via gel elec-
trophoresis in gradient polyacrylamide gels (Novex), and transferred
onto polyvinylidene difluoride membrane (Millipore). Membranes were
blocked in 1x Tris-buffered saline-Tween 20 buffer with 5% non-fat
milk (blocking solution), and then probed using primary antibodies
(Table 2) of the protein targets of interest, diluted in
the blocking solution. Secondary antibodies (Table 3) were used to de-
tect the species-specific portion of the primary antibody, diluted in the
blocking solution. Immuno-reactive bands were visualized using Super-
Signal West Dura Chemiluminescent Substrate (Thermo Scientific). Rel-
ative band intensity was calculated using ImageLab software (BioRad)
and normalized to the quantified total protein on each respective mem-
brane, as determined through Ponceau staining[42].
2.7. Measuring oxygen consumption rate using Seahorse mitochondrial flux
analyses
To measure mitochondrial function in BeWo cells, we employed the
Seahorse XFe24 analyzer to assess the oxygen consumption rate (OCR).
Cells were seeded onto XFe24 seahorse plates at a density of 1 × 10⁠5
cells per well and incubated with culture medium alone or culture
media treated with 15µM Δ9-THC for 24 h. Culture media were ex-
changed with unbuffered Seahorse XF base medium supplemented with
10 mM d-glucose, 2 mM L-glutamine, and 2 mM sodium pyruvate for
one hour prior to assay. After baseline OCR measurements (i.e. basal
respiration), we calculated different indices of mitochondrial function
from OCR measurements by the sequential injection of selective electron
transport chain inhibitors and uncoupling agents, including oligomycin
(1.5 ug/mL), 2,4-dinitrophenol (DNP) (50µM), a mixture of rotenone
(0.5µM) and antimycin A (0.5µM). The OCR values were normalized to
the amount of DNA content from each well using fluorescence Hoescht’s
stain. Briefly, cell lysates samples are diluted in 2x Hoescht ,33342
dye assay mix (0.0324 mM Hoescht Dye, 2 mM NaCl, 2 mM NaH⁠2PO⁠4)
and fluorescence was measured at 360 nm excitation with460 nm emis-
sion filters. DNA content was determined via a standard curve. Addition
of oligomycin reduces OCR and reflects respiration independent of ox-
idative phosphorylation. Addition of DNP stimulates electron transport
chain activity and maximal OCR (e.g. maximal respiration) and exposes
a reserve capacity for respiration (e.g. spare respiratory capacity). Ad-
dition of Rotenone/Antimycin A (e.g. mitochondrial chain complex in-
hibitors) indicates OCR independent of electron transport chain activ-
ity (i.e. proton leak). Each experiment was performed with 6 biological
replicates from 1 experiment, and repeated 3 more times.
2.8. Statistical analysis
All statistical analyses were performed using GraphPad Prism 5 soft-
ware. All results were expressed as means of normalized values ± SEM.
All experiments were replicated four times (n = 4). The significance
of the differences (p < 0.05) between normalized mean values were
then evaluated using one-way ANOVA followed by Tukey’s post-test or,
where indicated, an unpaired Student’s t-test.
Table 1
Forward and reverse sequences for the primers used for quantitative Real-Time PCR.
Gene Forward Reverse GenBank/Reference
Grp78 TGTCTTTTGTCAGGGGTCTTT CACAGTGGTGCCTACCAAGA NM_005347
Spliced Xbp1 CCGCAGCAGGTGCAGG GGGGCTTGGTATATATGTGG NM_005080.3
Atf6 TTGACATTTTTGGTCTTGTGG GCAGAAGGGGAGACACATTT XM_011509309.1
Atf4 CTATACCCAACAGGGCATCC GTCCCTCCAACAACAGCAAG NM_001675.4
CHOP TGATGCTCCCAATTGTTCATG TCGCCGAGCTCTGATTGAC NM_001195053.1
VEGFA ATGACGAGGGCCTGGAGTGTG CCTATGTGCTGGCCTTGGTGAG NM_001287044.1
ERRγ CTGACGGACAGCGTCAACC GGCGAGTCAAGTCCGTTCTG NM_001438
FLT-1 ACAATCAGAGGTGAGCACTGCAA TCCGAGCCTGAAAGTTAGCAA JX512442
FLK-1 GTGTCAGAATCCCTGCGAAGTA GAAATGGGATTGGTAAGGATGA NM_002253
NDI TGGGTACAATGAGGAGTAGG GGAGTAATCCAGGTCGGT MH449555.1
GAPDH AGGTCCACCACTGACACGTT GCCTCAAGATCATCAGCAAT NM_002046
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Table 2
Western Blot antibodies, dilutions used in experiments, and company and catalogue infor-
mation.
Antibody name Source Dilution Company (#Catalogue)
GRP78 Rabbit
monoclonal
1:1000 Cell Signaling Technology Inc.,
Danvers, Massachusetts
(#C50B12)
ATF4 Mouse
monoclonal
1:500 Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA
(#sc-390063)
CHOP Mouse
monoclonal
1:500 Cell Signaling Technology Inc.,
Danvers, Massachusetts (#L63F7)
P-eIF2α [Ser
51]
Rabbit
monoclonal
1:1000 Cell Signaling Technology Inc.,
Danvers, Massachusetts (3597)
CITRATE
SYNTHASE
Rabbit
polyclonal
1:1000 donated by Dr. Sandeep Raha at
McMaster University (Hamilton,
ON, Canada)
OXPHOS Mouse
monoclonal
1:500 Abcam (ab110413)
Table 3
Western Blot secondary antibodies, dilutions used in experiments, and company and cata-
logue information.
Antibody name Dilution Company (#Catalogue)
Donkey Anti-Rabbit
IgG (H + L)
1:10000 Jackson ImmunoResearch Laboratories, West
Grove, PA, USA (#711-001-003)
Donkey Anti-Mouse
IgG (H + L)
1:5000 Jackson ImmunoResearch Laboratories, West
Grove, PA, USA (#715-001-003)
3. Results
3.1. Δ9-THC induced ER stress in a dose-dependent manner
BeWo cells were treated with vehicle or increasing doses of Δ9-THC
(3–30 μM) for 24 h as previously performed [14,20]. Δ9-THC treatment
led to the activation of pathways in the UPR in a concetration-depen-
dent manner. At 24 h the steady state mRNA levels of the ER stress
markers GRP78 (Fig. 1A), spliced-XBP1 (Fig. 1C), ATF6 (Fig. 1E), and
ATF4 (Fig. 1F) were significantly increased by Δ9-THC at 15 and 30 μM
compared to vehicle control. The protein levels of GRP78 (Fig. 1B),
phosphorylated eIF2α [Ser51] (Fig. 1D), and ATF4 (Fig. 1G) were also
increased at 15 and 30 µM compared to vehicle. Downstream the UPR
pathway, the steady-state mRNA and protein levels of CHOP, a tran-
scription factor activated during chronic ER stress to upregulate apop-
totic pathways, was also significantly increased at 24 h (Fig. 1I).
3.2. Pre-treatment with CB1R/CB2R antagonist abrogated Δ9-THC-
induced ER stress in BeWo cells
To identify whether Δ9-THC mediated its effects on ER stress
through its cannabinoid receptors, BeWo cells were pretreated for 1 h
with 1 μM SR141716 (CB1R antagonist) and 0.1 μM SR144528 (CB2R
antagonist) and then treated with Δ9-THC (15 μM) for 24 h. Δ9-THC sig-
nificantly increased the steady-state mRNA levels of all ER stress mark-
ers (i.e., GRP78, spliced-XBP1, ATF6, ATF4, and CHOP) at 24 h (Fig.
2A-E); and this effect of Δ9-THC was completely blocked with CB1R/
CB2R antagonists, except for ATF6 mRNA (Fig. 2C), which was partially
blocked. Interestingly, treatment with BeWo cells with equimolar con-
centrations of 11−COOH-THC, the major Δ9-THC metabolite, had no ef-
fects on any ER stress markers after 24 h (Fig. 2A-E).
3.3. Pre-treatment with TUDCA alleviated the effects of Δ9-THC-induced
ER stress and downstream ER stress target genes in BeWo cells
To determine whether Δ9-THC-induced ER stress could be pre-
vented, the bile acid TUDCA, previously demonstrated to ameliorate
placental ER stress (i.e. suppress PERK pathway) was employed [25,35].
BeWo cells were pretreated for 1 h with 100 μM of TUDCA and then
treated with Δ9-THC (15 μM) for 24 h. Δ9-THC significantly increased
steady-state mRNA levels of ER stress markers (i.e., GRP78,
spliced-XBP1, ATF6, ATF4, and CHOP) at 24 h while TUDCA pretreat-
ment completely abrogated this effect (Fig. 3A-E). There was no ef-
fect on ER stress markers with TUDCA pretreatment alone (Fig. 3A-E).
To examine whether Δ9-THC mediated ER stress may result in im-
paired placental function, we next examined if established ER stress tar-
get genes were altered downstream. After 24 h, Δ9-THC increased the
steady-state levels of ERRγ and VEGFA mRNA (Fig. 3F-G), two genes
demonstrated to be up-regulated by ER stress [43–45]. Moreover, pre-
treatment with TUDCA abrogated the effects of Δ9-THC (Fig. 3F-G).
TUDCA also blocked the stimulatory effect of Δ9-THC on the expression
of FLT-1 (VEGFR-1, Fig. 3H), while FLK-1 (VEGFR-2) mRNA could not
be detected (data not shown). It is noteworthy that treatment of BeWo
cells with COOH-THC had no effect on ERRγ, VEGFA, or Flt-1 mRNA
levels compared to vehicle (Fig. 3F-H).
3.4. Δ9-THC treatment decreases mitochondrial respiration and ATP
coupling efficiency in BeWo cells
Given the links between ER stress and mitochondrial dysfunction
in trophoblast cells [33], we next investigated if Δ9-THC impairs mi-
tochondrial respiration using the XFe24 Seahorse analyzer to measure
OCR (Fig. 4A). After 24 h in culture, 15 µM Δ9-THC significantly low-
ered basal respiration by 50% (Fig. 4B, p < 0.001), maximal respira-
tion by 25% (Fig. 4C, p < 0.05), ATP-synthase-linked respiration by
50% (Fig. 4E, p < 0.001), and ATP coupling efficiency by 25% (Fig.
4G, p < 0.05) in BeWo cells. However proton leak (Fig. 4D) and mito-
chondrial spare capacity (Fig. 4F) was not different between vehicle and
Δ9-THC treated cells.
3.5. Δ9-THC treatment decreases the expression of mitochondrial complex
proteins in BeWo cells
Since mitochondrial respiration and ATP coupling efficiency was di-
minished by Δ9-THC, we next pursued if decreases in mitochondrial
number, mass, and mitochondrial complex proteins might account for
mitochondrial dysfunction. After 24 h in culture, 15 µM Δ9-THC did
not significantly alter the mtDNA expression of ND-1 (Fig. 5A), an in-
dicator of total mitochondrial number [46,47]. However, Δ9-THC de-
creased citrate synthase protein levels by 25% (Fig. 4B, p < 0.05), a
marker of total mitochondrial mass, compared to vehicle controls [48].
In addition, 15 µM Δ9-THC led to lower protein levels of ATP5 A (part
of mitochondrial protein complex V, 50% decrease, Fig. 5D, p < 0.05),
MTCO1 (part of mitochondrial protein complex IV, 50% decrease, Fig.
5E, p < 0.05), UQCRC2 (part of mitochondrial complex III, 30% de-
crease, Fig. 5F, p < 0.05), and NDUFB8 (part of mitochondrial complex
I, 30% decrease, Fig. 5H, p < 0.05). SDH8 (part of mitochondrial com-
plex II) protein levels were not significantly different between vehicle
and Δ9-THC-treated cells (Fig. 5G).
4. Discussion
In this study, we demonstrated that bioactive Δ9-THC (and not its
inactive metabolite) can directly augment ER stress in a human tro-
phoblast cell line as indicated through the dose-dependent increases in
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Fig. 1. Δ 9-THC increases ER stress in human BeWo trophoblast cells. Real-time qPCR of human BeWo cells were treated with either vehicle or Δ9-THC (3–30 μM) for 24 h. Total
RNA was extracted and reverse-transcribed to cDNA and normalized to GAPDH. For protein analysis, specific targeted protein bands were detected by respective antibodies via Western
blot and normalized by PONCEAU staining. A. GRP78 mRNA, B. GRP78 protein, C. splied-XBP1 mRNA, D. pEIF2α [Ser51], E. ATF6 mRNA, F. ATF4 mRNA, G. ATF4 protein, H. CHOP
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mRNA, and I. CHOP protein. All values were expressed as mean ± SEM (N = 6/group). Significant differences between treatment groups determined by 1-way ANOVA. Different letters
represent means that are significantly different from one another according to Tukey’s posttest (P < .05).
Fig. 2. Pretreatment with CB1R/CB2R antagonists abrogates Δ9-THC-induced ER stress. Real-time qPCR of human BeWo cells were treated with 15 μM Δ9-THC with or without
1 μM SR141716 and 0.1 μM SR144528 antagonists. Total RNA was extracted and reverse-transcribed to cDNA. A. GRP78 mRNA, B. splied-XBP1 mRNA, C. ATF6 mRNA, D. ATF4 mRNA,
and E. CHOP mRNA. All values were expressed as mean ± SEM (N = 3/group). Significant differences between treatment groups determined by 1-way ANOVA. Different letters represent
means that are significantly different from one another according to Tukey’s posttest (P < .05).
ER stress markers GRP78, spliced-XBP1, ATF6, ATF4, and CHOP. The
involvement of cannabinoid receptors CB1R and CB2R was further veri-
fied with the inhibition of Δ9-THC-induced ER stress using CB1R/CB2R
antagonists. This is the first time Δ9-THC has been demonstrated to in-
duce ER stress in a non-neuronal cell type [49]. We further revealed that
Δ9-THC, through increases in ER stress, can augment the expression of
key ER-stress sensitive genes ERRγ, VEGFA, and FLT-1, suggesting pos-
sible alterations in placental function. Given the links between ER stress
in placenta and mitochondrial dysfunction [33], it also interesting that
Δ9-THC led to impaired mitochondrial respiration and ATP coupling ef-
ficiency, in part due to decreased mitochondrial complex proteins.
Since ER stress and placental deficiency have been observed to pre-
cede intrauterine growth restriction, the presence of augmented ER
stress in human BeWo placental cells reveals a potential mechanism
through which Δ9-THC in pregnancy may result in adverse placental
and fetal outcomes [23–26]. Employing concentrations of Δ9-THC that
are found to be equivalent to those doses in the serum of cannabis users,
this led to the activation of three major branches in the ER stress path-
way [20,34]. Increased steady-state mRNA levels of ATF6 proposes in-
volvement of the ATF6 branch, which downstream would lead to further
expression of ER chaperone proteins, including GRP78 [21]. Likewise,
increased mRNA expression of spliced-XBP1 indicates the activation
of IRE‐1 pathway implicated in downstream upregulation of ER chap-
erones and protein degradation [21]. Δ9-THC also increased the lev-
els of phosphorylated eIF2α [Ser51] suggesting activation of the PERK
pathway and protein translation attenuation as another means of try-
ing to relieve ER stress. The decrease in protein translation may ex-
plain why Δ9-THC is able to diminish both proliferation and migra-
tion in BeWo cells [14,20]. It should be noted that for the current and
published Δ9-THC studies in BeWo cells, the experiments were con-
ducted in 21% atmospheric O⁠2, which leads to ˜0.5–9% dissolved oxy-
gen concentrations depending on the depth of media [14,20,50]. While
Δ9-THC induced ER stress in BeWo cells with similar oxygen concen
trations, further studies are warranted to address if alterations in oxy-
gen concentrations influences the degree of ER stress given hypoxia is
a distinct trigger of placental ER stress [24,51]. Moreover, the potential
role for ER stress on Δ9-THC induced impairment of invasion and mi-
gration in extravillous trophoblasts (e.g. HTR8/SNneo cells) should also
be explored [14,36].
Under conditions of prolonged ER stress that is not resolved, the UPR
switches to initiate apoptosis [52]. CHOP, regulated by both ATF4 and
ATF6, is known to be involved in ER stress induced apoptosis and am-
plifies various downstream apoptotic pathways [52]. We observed that
Δ9-THC also augmented both the mRNA and protein levels of ATF4,
leading to increased CHOP levels in BeWo cells, suggesting apoptosis
has been initiated. The Δ9-THC induction of protein attenuation (e.g.
phosphorylated eIF2α [Ser51]) and CHOP in BeWo cells may shed some
light to the observed decrease in placental and fetal weights derived
from pregnant mouse dams treated with Δ9-THC during gestation [14].
Further studies are warranted to investigate more downstream apop-
totic markers (i.e. Caspases 3, 9, 12, and BCL-2) to evaluate the extent of
Δ9-THC- induced ER stress apoptosis. It is noteworthy that the ER stress
observed was specific to active Δ9-THC given equimolar concentrations
of COOH-THC did not exert any significant changes in hallmarks of the
UPR.
Considering that Δ9-THC directly augmented placental ER stress, we
were next interested in investigating the effects of Δ9-THC on critical
placental target genes known to be altered by ER stress. We demon-
strated that the Δ9-THC, but not its major metabolite COOH-THC, in-
duces the expression of ERRγ, VEGFA, and FLT1 (VEGFR-1) in BeWo
cells; and that this could be ameliorated with inhibition of ER stress
(e.g. TUDCA). Interestingly, it is well established that the expression
of the nuclear receptor ERRγ is increased by ER stress-induced ATF6,
and that ERRγ itself can bind to the promoter of ATF6 to up-reg-
ulate its own expression, in a positive feed-forward loop [43]. It is
also possible that Δ9-THC may directly induce ERRγ expression given
activation of CB1R has been shown to induce hepatic
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Fig. 3. Pre-treatment with TUDCA alleviated the effects of Δ9-THC-induced ER stress. Real-time qPCR of human BeWo cells were pretreated with 100 μM of TUDCA for 1 h and then
treated with 15 μM Δ9-THC for 24 h. In addition, cells were also treated with 15 µM 11−COOH-THC for 24 h. Total RNA was extracted and reverse-transcribed to cDNA. A. GRP78 mRNA,
B. spliced-Xbp1 mRNA, C. ATF6 mRNA, D. ATF4 mRNA, E. CHOP mRNA, F. ERRγ mRNA, G. VEGA mRNA, and H. FLT-1 (VEGFR-1) mRNA. All values were expressed as mean ± SEM
(N = 3/group). Significant differences between treatment groups determined by 1-way ANOVA. Different letters represent means that are significantly different from one another accord-
ing to Tukey’s posttest (P < .05).
ERRγ expression [53]. Previous studies have demonstrated that acti-
vation of placental ERRγ leads to elevated maternal blood pressure
which is noteworthy considering the expression of ERRγ is higher in
preeclamptic placentas, a condition which is also associated with aug-
mented ER stress in the placenta [27,28,54]. Paradoxically, the ele-
vated ERRγ did not improve mitochondrial function in Δ9-THC-treated
cells, despite its known role to promote mitochondrial biogenesis dur-
ing trophoblast differentiation [55]. This may be due to the fact that
these BeWo cells were not induced to differentiate in this experimen-
tal paradigm. With respect to VEGFA and FLT-1 (VEGFR-1), it has
been established that elevated ER stress increases VEGFA expression via
ATF4 and XBP-1 binding to the proximal promoter of VEGFA, while
ER stress inhibitors can diminish VEGFA expression [44,45,56,57]. In-
terestingly, pharmacological induction of ER stress by tunicamycin in
pregnancy results in higher protein levels of Vegfa in the spongiotro-
phoblast layer of the mouse placenta, while lipopolysaccharide-induced
ER stress also leads to augmented placental Vegfa expression [29,58].
It should be noted that in those studies the protein levels of placen-
tal Flt-1T were not examined. In BeWo cells, the Δ9-THC-induction
of VEGFA and FLT-1 may occur as a compensation to indirectly re-
lieve ER stress given VEGFA promotes XBP1 splicing and angiogene-
sis in endothelial cells [59]. Certainly future rodent studies are war-
ranted to examine if maternal exposure to Δ9-THC in vivo leads to pla-
cental zone-specific alterations in ER stress and downstream prolifer-
ation and angiogenesis. Given that TUDCA can relieve placental ER
stress induced by nicotine, high glucose, and now Δ9-THC, it will also
be of great interest to examine if TUDCA in vivo can prevent the ad
verse effects of maternal Δ9-THC exposure on trophoblast function and
fetal development [14,25,35].
Mitochondria are responsible for providing the majority of cellular
energy in the form of ATP. The inner membranes of these organelles
provide the various proteins required for ATP synthesis, and via the
transfer of proteins in the electron transport chain, ATP synthesis oc-
curs due to oxidative phosphorylation [60]. Impaired placental mito-
chondrial function has been associated with fetal growth restriction and
preeclampsia [61–65]. Given the close approximation of the ER and mi-
tochondria in punctate sites known as the mitochondrial-associated ER
membrane (MAM), it has been suggested integrated signaling occurs be-
tween both organelles [66]. As calcium transporters and ion channels
are concentrated in the MAM, calcium-mediated ER signals can influ-
ence both mitochondrial electron transport chain activity and ATP pro-
duction to meet the protein synthesis demands of the ER [33]. Since
ER and mitochondrial functions are coupled via MAMS, so too is ER
and mitochondrial stress [67,68]. After discovering that Δ9-THC in-
duced ER stress in BeWo cells, we further demonstrated that mitochon-
drial oxidative metabolism was impaired. Specifically, Δ9-THC elicited
decreases in basal and maximal mitochondrial respiration, ATP-syn-
thase-linked respiration, and ATP coupling efficiency. This Δ9-THC in-
duced defect in the electron transport chain activity may be attrib-
uted to the observed decreases in the abundance of mitochondria com-
plex proteins (e.g. I, III, IV, and V) and mitochondrial mass (as re-
flected by the decrease in citrate synthase expression) [48]. In other
cell types, activation of the cannabinoid receptors can reduce mito-
chondrial function. [69–72]. For example, Δ9-THC or synthetic CBR re
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Fig. 4. Δ9-THC decreases mitochondrial function in cultured BeWo human trophoblast cells. Seahorse XFe24 analyzer was used to measure the oxygen consumption rate of cultured
BeWo trophoblasts. Cells were seeded onto XFe24 seahorse plates at 1 × 10⁠5 cells per well and incubated with culture medium alone or culture media treated with 15µM Δ9-THC for 24 h.
Culture media were exchanged with unbuffered Seahorse media supplemented with 10 mM d-glucose, 2 mM L-glutamine, and 2 mM sodium pyruvate for one hour prior to assay. To mea-
sure different oxygen consumption rate (OCR) parameters selective inhibitors were injected, oligomycin (1.5 ug/mL), 2,4-Dinitrophenol (DNP, 50µM), rotenone (0.5µM) and antimycin A
(0.5 µM). Addition of oligomycin reduces OCR and reflects respiration independent of oxidative phosphorylation. Addition of DNP stimulates electron transport chain activity and maximal
OCR. Addition of Rotenone/Antimycin A (mitochondrial chain complex inhibitors) indicates OCR independent of mitochondrial metabolism. Mitochondrial spare capacity was calculated
from the change in OCR following DNP-stimulated maximal respiration. The OCR values were normalized to the amount of DNA content from each well using fluorescence Hoescht’s
stain. Data are presented as the mean of 6 biological replicates from 1 experiment, repeated 3 more times (see Supplemental Fig. 1 for experiments 2-4). Mean ± SEM, Significance was
assessed by Student’s t-test (*P < 0.05). A. Representative oxygen consumption rate (OCR) tracing. B. Basal respiration, C. Maximal respiration, D. Proton leak, E. ATP-linked production,
F. Spare respiratory capacity, G. ATP coupling efficiency.
ceptor agonists (e.g. ARA and HU 210) in the H460 human lung cell line
diminished mitochondrial oxygen consumption, complex I, and com-
plex II/III activity [69]. Further studies are warranted to assess the spe-
cific contributions of Δ9-THC-induced ER stress towards to mitochon-
drial dysfunction observed. To date there is some debate regarding pla-
cental insufficiency and type of mitochondrial dysfunction. In small
for gestational age (SGA) pregnancies, placentae exhibited lower mito-
chondrial mass (e.g. decreased citrate synthase activity), while another
study demonstrated that intrauterine growth restricted (IUGR) placen-
tae had higher mitochondrial content, oxygen consumption, and mito-
chondrial complex protein activity (e.g. complex I,III, and IV) [61,62].
In IUGR pigs the placental mitochondrial content was diminished, while
in a rabbit model of fetal growth restriction, decreases in placental
mitochondrial complex II, and II/III was observed without any effects
on mitochondrial content [64,73]. The observed ability of Δ9-THC
to impede mitochondrial function in vitro may account for the pla-
cental insufficiency (e.g. decreased placental and fetal weights) ob-
served in vivo given pharmacological inhibition of mitochondrial func-
tion in the mouse preimplantation embryo led to lower mitochondrial
respiration rate, ATP synthesis, and placental growth [14,74]. Collec
tively, this would suggest that Δ9-THC could reduce placental size and
efficiency via defects to both ER and mitochondrial function.
In conclusion, this study has demonstrated for the first time that
Δ9-THC directly induces ER stress in the placenta. With the use of hu-
man BeWo placental cells, we were able to provide insight on the ef-
fects of Δ9-THC exposure on placental ER stress, and its downstream ef-
fects linked to aberrant trophoblast gene expression and associated mi-
tochondrial dysfunction. Moreover, we revealed that Δ9-THC-induced
ER stress can be alleviated with TUDCA supplementation, demonstrat-
ing a potential therapeutic option for treating the negative effects of
maternal cannabis exposure. Further studies are warranted to address
whether Δ9-THC leads to ER stress in vivo and if this mediates the
placental insufficiency which has been previously reported and/or if
Δ9-THC-induced placental ER stress has long-term effects on offspring
health. Moreover, given the strong links between Δ9-THC, ER and
mitochondrial dysfunction, it will also be critical to further examine
if exposure to Δ9-THC during gestation impairs the development of
other fetal organs as diminished fetal cardiac mitochondrial function
is observed in a rabbit model of placental-insufficiency induced IUGR
[73]. With the increasing world-wide use of cannabis in pregnancy and
higher concentrations of Δ9-THC, these studies are imperative to fur
8
UN
CO
RR
EC
TE
D
PR
OO
F
T. Lojpur et al. Reproductive Toxicology xxx (xxxx) xxx-xxx
Fig. 5. Δ9-THC Decreases Expression of Citrate Synthase and Mitochondrial Complex Proteins in Cultured BeWo Human Trophoblast Cells. Cells were with culture medium
alone or culture media treated with 15 µM Δ9-THC for 24 h. A. Total RNA was extracted and reverse-transcribed to cDNA and A. NADH:Ubiquinone oxidoreductase core subunit V1 was
normalized to GAPDH. For proteins analysis, cell lysates were extracted and run on an immunoblot for B. Citrate Synthase. C. Representative OXPHOS Mitochondrial Complex Proteins
(I–V) Blot. D. Complex V protein, E. Complex IV protein, F. Complex III protein, G. Complex II protein, and H. Complex I protein. All proteins were normalized by PONCEAU staining.
Mean ± SEM, Significance was assessed by Student’s t-test (*P < 0.05), N = 3/group.
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ther understand the risk of Δ9-THC exposure on fetal and postnatal out-
comes.
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